A 12-month, Interventional, Open-label, Phase 4 Study in Europe (SHINE) to Investigate the Course of Synovial Hypertrophy as Detected by Joint Ultrasound and MRI in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis.
Latest Information Update: 14 Jan 2025
Price :
$35 *
At a glance
- Drugs Efanesoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms SHINE
- 08 Jan 2025 Status changed from not yet recruiting to recruiting.
- 08 Jan 2025 New trial record